Posted On: 01/25/2016 7:42:38 PM
Post# of 23074
$EPRS upturn
Nasdaq GM $3.28
Website
Shares Outstanding: 24.38M
Float: 13.54M
% Held by Insiders: 19.98%
% Held by Institutions: 60.30%
Shares Short (as of Dec 31, 2015): 757.71K
Short Ratio (as of Dec 31, 2015): 3.02
Short % of Float (as of Dec 31, 2015): 4.14%
Shares Short (prior month): 939.03K
Headlines
EPIRUS Biopharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. The companys pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) to treat inflammatory diseases, including rheumatoid arthritis and various other forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis and psoriasis; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment of rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis. It has a license agreement with Ranbaxy Laboratories Limited; license and collaboration agreement with Livzon Mabpharm Inc.; and license agreement with Bioceros B.V. The company is headquartered in Boston, Massachusetts.
Nasdaq GM $3.28
Website
Shares Outstanding: 24.38M
Float: 13.54M
% Held by Insiders: 19.98%
% Held by Institutions: 60.30%
Shares Short (as of Dec 31, 2015): 757.71K
Short Ratio (as of Dec 31, 2015): 3.02
Short % of Float (as of Dec 31, 2015): 4.14%
Shares Short (prior month): 939.03K
Headlines
EPIRUS Biopharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. The companys pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) to treat inflammatory diseases, including rheumatoid arthritis and various other forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis and psoriasis; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment of rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis. It has a license agreement with Ranbaxy Laboratories Limited; license and collaboration agreement with Livzon Mabpharm Inc.; and license agreement with Bioceros B.V. The company is headquartered in Boston, Massachusetts.
(0)
(0)
